These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 173458)

  • 21. Immunologic assays in lung cancer. Skin tests, lymphocyte blastogenesis, and rosette-forming cell count.
    Brugarolas A; Han T; Takita H; Minowada J
    N Y State J Med; 1973 Mar; 73(6):747-50. PubMed ID: 4510958
    [No Abstract]   [Full Text] [Related]  

  • 22. Parameters of T cell mediated immunity to commensal micro-organisms in patients with chronic purulent rhinosinusitis: a comparison between delayed type hypersensitivity skin test, lymphocyte transformation test and macrophage migration inhibition factor assay.
    van de Plassche-Boers EM; Drexhage HA; Kokjé-Kleingeld M; Leezenberg HA
    Clin Exp Immunol; 1986 Dec; 66(3):516-24. PubMed ID: 3552334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant immunotherapy in bronchogenic carcinoma.
    Takita H; Minowada J; Han T; Takada M; Lane WW
    Ann N Y Acad Sci; 1976; 277(00):345-54. PubMed ID: 1069554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoprofile studies for patients with bronchogenic carcinoma--III. Multivariate analysis of immune tests in correlation with survival.
    Concannon JP; Dalbow MH; Davis W; Hodgson SE; Mitchell J; Markopoulos E
    Int J Radiat Oncol Biol Phys; 1978; 4(3-4):255-61. PubMed ID: 646868
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunologic status in lung cancer.
    Brugarolas A; Takita H
    Chest; 1973 Oct; 64(4):427-30. PubMed ID: 4355273
    [No Abstract]   [Full Text] [Related]  

  • 26. Monitoring of nonspecific cell-mediated immunity in cancer patients. I. Frequent dissociation between the responses of skin tests to recall antigens and in vitro lymphocyte transformation.
    Simmler MC; Rameau G; Chou MJ; Mathé G
    Isr J Med Sci; 1976; 12(4-5):472-8. PubMed ID: 939695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody in sera of pulmonary cancer patients against specific surface antigen of oat cells.
    Oboshi S; Seido T; Tsugawa S
    Gan; 1971 Dec; 62(6):515-22. PubMed ID: 4334635
    [No Abstract]   [Full Text] [Related]  

  • 28. Preoperative cell-mediated immune status of gastric cancer patients.
    Orita K; Miwa H; Fukuda H; Yumura M; Uchida Y
    Cancer; 1976 Dec; 38(6):2343-8. PubMed ID: 793709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of therapeutic irradiation on the immune responses].
    Imajo Y; Gose K; Ichiyanagi A; Kimura S; Ogawa Y; Imanaka K
    Gan No Rinsho; 1983 Oct; 29(13):1512-20. PubMed ID: 6668663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma glutamate levels, lymphocyte reactivity and death rate in patients with bronchial carcinoma.
    Eck HP; Drings P; Dröge W
    J Cancer Res Clin Oncol; 1989; 115(6):571-4. PubMed ID: 2558118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Demonstration of specific cell-mediated anti-tumor immunity in lung cancer to autologous tissue extracts.
    Dean JH; Jerrells TR; Cannon GB; Kibrite A; Baumgardner B; Weese JL; Silva J; Herberman RB
    Int J Cancer; 1978 Oct; 22(4):367-77. PubMed ID: 212376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-specific immunostimulation in bronchogenic cancer.
    Israel L
    Scand J Respir Dis Suppl; 1974; 89():95-105. PubMed ID: 4370224
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunosuppressive effects of glucocorticosteroids: differential effects of acute vs chronic administration on cell-mediated immunity.
    Balow JE; Hurley DL; Fauci AS
    J Immunol; 1975 Mar; 114(3):1072-6. PubMed ID: 803535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoprofile studies for patients with bronchogenic carcinoma. I. Correlation of pretherapy studies with survival.
    Liebler GA; Concannon JP; Magovern GJ; Dalbow MH; Hodgson SE
    J Thorac Cardiovasc Surg; 1977 Oct; 74(4):506-18. PubMed ID: 302883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoprofile studies for patients with bronchogenic carcinoma--I: correlation of pre-therapy studies with stage of diseases.
    Concannon JP; Dalbow MH; Eng CP; Conway J
    Int J Radiat Oncol Biol Phys; 1977; 2(5-6):447-54. PubMed ID: 301875
    [No Abstract]   [Full Text] [Related]  

  • 36. Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters.
    Redondo M; Concha A; Oldiviela R; Cueto A; Gonzalez A; Garrido F; Ruiz-Cabello F
    Cancer Res; 1991 Sep; 51(18):4948-54. PubMed ID: 1654207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunologic detection of bronchial cancer?].
    Muhrer KH; Effenhauser P; Pasurka B
    Prax Klin Pneumol; 1983 Oct; 37 Suppl 1():995-7. PubMed ID: 6647382
    [No Abstract]   [Full Text] [Related]  

  • 38. Tumor associated antigen with pulmonary neoplasms.
    Lo Gerfo P; Herter FP; Braun J; Hansen HJ
    Ann Surg; 1972 Apr; 175(4):495-500. PubMed ID: 4336486
    [No Abstract]   [Full Text] [Related]  

  • 39. The relationship between immune reactivity, serum cortisol, and stage of disease in patients with non-oat-cell bronchogenic carcinoma.
    DeMeester TR; Golomb HM; Dudek P; Hunter RL; Fang VS
    Surgery; 1979 Jul; 86(1):130-7. PubMed ID: 572099
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunocompetence in lung cancer. Relationship to extent of tumor burden and histologic type.
    Pillai MR; Balaram P; Padmanabhan TK; Abraham T; Hareendran NK; Nair MK
    Cancer; 1989 Nov; 64(9):1853-8. PubMed ID: 2551475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.